Vertex Pharmaceuticals Inc (VRTX)

VRTX (NASDAQ:Drugs) EQUITY
$131.26
pos +0.00
+0.00%
Today's Range: 126.00 - 132.00 | VRTX Avg Daily Volume: 1,424,800
Last Update: 07/02/15 - 3:59 PM EDT
Volume: 0
YTD Performance: 10.49%
Open: $0.00
Previous Close: $126.19
52 Week Range: $84.41 - $137.50
Oustanding Shares: 243,752,247
Market Cap: 30,759,096,049
6-Month Chart
TheStreet Ratings Grade for VRTX
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 7 7 7 8
Moderate Buy 1 1 1 1
Hold 10 10 10 10
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.17 2.17 2.17 2.11
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: -42.49
Price Earnings Comparisons:
VRTX Sector Avg. S&P 500
-42.49 0.00 26.13
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
11.97% 33.90% 136.25%
GROWTH 12 Mo 3 Yr CAGR
Revenue -52.10 -0.59 -0.25
Net Income 0.00 -19.01 0.00
EPS 0.00 -23.43 0.00
Earnings for VRTX:
EBITDA -0.64B
Revenue 0.58B
Average Earnings Estimates
Qtr (06/15) Qtr (09/15) FY (12/15) FY (12/16)
Average Estimate $-0.76 $-0.45 $-2.12 $3.91
Number of Analysts 4 4 4 4
High Estimate $-0.66 $-0.17 $-1.35 $7.89
Low Estimate $-0.90 $-0.88 $-3.33 $0.57
Prior Year $-0.79 $-0.57 $-2.93 $-2.12
Growth Rate (Year over Year) 3.16% 21.49% 27.56% 284.33%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
By

Dan Fitzpatrick

 | May 27, 2015 | 5:00 PM EDT

Sector may not be as bulletproof as we thought.

By

Jim Cramer

 | May 13, 2015 | 11:17 AM EDT

Jim Cramer answers viewers' stock questions from the floor of the New York Stock Exchange.

bullishVertex estimates, target increased at Leerink

Apr 30, 2015 | 7:49 AM EDT

VRTX estimates were raised through 2016, Leerink Partners said. Orkambi should drive near-term growth. Outperform rating and new $150 price target. 

By

Jim Cramer

 | Apr 21, 2015 | 3:44 PM EDT

Biotech companies are saying, "I do."

By

David Katz

 | Apr 21, 2015 | 1:05 PM EDT

Teva bid highlights M&A action in health care sector.

By

David Katz

 | Apr 21, 2015 | 12:53 PM EDT

Teva bid highlights M&A action in health care sector.

bullishVertex rated new Buy at Canaccord Genuity

Apr 10, 2015 | 7:29 AM EDT

VRTX was initiated with a Buy rating, Canaccord Genuity said. $150 price target. Company has an attractive pipeline, strong balance sheet and should achieve profitability later this year. 

By

Jim Cramer

 | Apr 8, 2015 | 3:46 PM EDT

Even the second-tier biotechs are taking off.

By

Jim Cramer

 | Mar 23, 2015 | 6:00 AM EDT

Here are healthcare stocks of all shares and sizes with strong charts.

bullishVertex upgraded at Piper

Oct 13, 2014 | 7:55 AM EDT

VRTX was upgraded from Neutral to Overweight, Piper Jaffray said. $125 price target. Expect combination approvals in 2015.

Sorry folks. I received a few queries concerning my earlier note on IMF nullification of t...
It appears that the International Monetary Fund has preemptively nullified the referendum ...
Earlier today we added some IWM puts, this being the 'weakest' performing index this week,...
Forget Greece, forget economic data, forget everything. Just give me my burrito. CMG con...

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.